drugset / Trial / NCT04888715

To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers

NCT04888715

Phase 1 Completed 48 enrolled Daewoong Pharmaceutical Co. LTD.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers

Timeline

Start
2021-07-23
Primary completion
2021-08-02
Completion
2021-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BERSIPOROCIN Small molecule Oral
Subject Nintedanib Small molecule Oral
Subject Pirfenidone Small molecule Oral